Cross-border antibiotic resistance: the AMR you can bring home from medical tourism

Carrying a resistant organism is not the same as being made sick by one, and I want to put that distinction at the front of this piece so that nothing here gets read as a claim that everyone who flies abroad for care comes home infected. They do not. Most people who travel for a procedure return uneventfully, heal normally, and never carry anything of consequence. The body is host to vast populations of bacteria at the best of times, and the presence of a difficult organism is not, by itself, an illness.

So I am not going to argue that medical tourism gives you an infection. I am going to argue something narrower and, I think, more honest: that medical tourism is a recognised route by which a person can acquire a multidrug-resistant organism abroad and carry it home, unscreened and unmonitored, into a health system that has no idea it has arrived. The hazard I am describing is not the dramatic one. It is the quiet one: importation without surveillance. The organism crosses a border in a person who feels perfectly well, and the danger only materialises later, when nobody thought to look for it.

What resistance actually is, in plain terms

Antimicrobial resistance is, in the CDC’s plain definition, what happens when germs such as bacteria and fungi defeat the drugs designed to kill them [1]. The drugs stop working against those particular organisms, so an infection that would once have been routine to treat becomes difficult, expensive, or in the worst cases untreatable with the usual options. The WHO treats this as one of the defining public health threats of the era, a global problem rather than a local one [2].

Two features of resistance make it a cross-border issue rather than a contained one. First, resistant organisms spread, the CDC notes, between people, animals and the environment [1]. They do not respect national boundaries, because the people and goods that carry them do not. Second, resistance prevalence is genuinely uneven across regions and across healthcare settings; the organisms that are common in one hospital system may be rare in another [3]. Put those two facts together and you have the precondition for the entire problem: a traveller can pick up, in a higher-prevalence setting, an organism that is uncommon at home, and then physically transport it across the boundary that was supposedly keeping the two epidemiologies separate.

This is not a moral judgement about any country. It is geography plus biology. Different places harbour different organisms, and people move between them.

Colonisation versus infection, and why the quiet phase matters

The single most important concept here, and the one most often glossed over, is the difference between colonisation and infection.

Colonisation means a resistant organism is simply present on or in your body, very often in the gut, without causing any symptoms. You feel fine. You have no fever, no wound problem, no illness. Infection means that organism has crossed from passenger to pathogen and is actively causing disease. The crucial point is that colonisation can precede infection, and a colonised person can later develop an infection from the very organism they have been quietly carrying, particularly under the stress of a future operation, an injury, or an illness that lowers their defences. A colonised person can also transmit the organism to others, including in a household or, more seriously, in a hospital.

So when I concede that colonisation is not infection, I am not conceding that it is harmless. I am identifying why it is dangerous in a specific way: because it is silent. An infection announces itself and gets treated. Colonisation announces nothing. It sits in the gut of a healthy-feeling traveller, undetected, until a future event turns it into a problem in a setting that never suspected it was there. The importation is real precisely because it is invisible.

Why medical tourism is a recognised route

Medical tourism, the practice of travelling across borders to obtain medical or dental care [4], assembles almost every ingredient that the resistance literature flags as a risk for acquiring a resistant organism.

Consider the components of a typical procedure abroad. There is an invasive intervention, which breaches the body’s barriers. There are frequently antibiotics given around the time of surgery, and antibiotic exposure is itself a driver of resistance, because it clears the susceptible organisms and leaves room for the resistant ones to flourish [3]. There may be a stay in a hospital or clinic, which is one of the classic environments for acquiring resistant organisms. And all of this may take place in a region where the local prevalence of certain resistant organisms is higher than at home. Each of those factors is, on its own, a recognised risk. Stacked together in a single trip, they describe close to a textbook scenario for acquisition.

Then comes the part unique to tourism: the journey home. The patient leaves the local health system, with its local knowledge of which organisms circulate there, and re-enters a different system that has no record of the procedure and no reason to suspect anything unusual. I have written about this loss of the local safety net in other contexts, the way flying home strips away the regulator, the records and the follow-up, in the dental tourism trust gap and in when to go overseas for dental treatment. Resistance is the version of that problem that is literally invisible: there is nothing to see at the border, and no symptom to report, yet the epidemiological boundary has been crossed.

The honest limits of what I can tell you

I have to be careful here, because antimicrobial resistance is exactly the kind of topic that invites invented numbers, and I will not give you one.

What is genuinely documented: resistance is a recognised global, cross-border problem [1][2]; resistant organisms spread between people and across regions [1][3]; antibiotic exposure and invasive care are recognised drivers and routes of acquisition [3]; and published case reports describe patients returning from care abroad carrying multidrug-resistant organisms. That much is solid and I am comfortable standing on it.

What I cannot give you is a single reliable figure for “the percentage of dental tourists who come home colonised,” because no such clean, generalisable number exists, and any precise statistic you see attached to this question deserves your suspicion. The risk is real and recognised; its exact magnitude for any individual depends on where they were treated, what was done, what antibiotics they received, and their own health. Conceding that uncertainty is the honest position. The case does not rest on a scary percentage. It rests on the documented existence of the route and the documented invisibility of the importation.

THE IMPORTATION PATHWAY (what is documented vs not)

  DOCUMENTED / recognised
  ------------------------------------------------------
  - Resistance is a global, cross-border problem
  - Resistant organisms spread person-to-person, region-to-region
  - Antibiotics + invasive care + facility stay raise acquisition risk
  - Case reports: patients return from care abroad carrying MDROs
  - Colonisation can be silent and can precede later infection

  NOT a reliable single number
  ------------------------------------------------------
  - "X% of dental tourists come home colonised"  <-- do not trust
  - Any precise per-patient probability                this kind of
                                                       claim

  THE LEVER YOU CONTROL
  ------------------------------------------------------
  - Whether the importation stays INVISIBLE to your home clinicians

The questions that change the answer

Three questions, mostly directed at your own clinicians rather than the overseas clinic, move this from an invisible risk to a managed one.

1. “Did I have invasive care, antibiotics, or a facility stay abroad that my home doctor should know about?” This is a self-audit. If the answer to any part is yes, then the history is relevant, and the single most protective thing you can do is make sure it does not stay hidden in your own memory.

2. “Should I be screened, or flagged for infection-control precautions, given where and how I was treated?” Raise this with your own doctor, particularly before any future hospital admission. There is no universal rule, but the decision should be made by a clinician who knows the history, not defaulted to silence because nobody asked.

3. “What records can I bring home so my clinicians can interpret a later fever or non-healing wound correctly?” A resistant organism that the treating team is primed to consider is a manageable problem. One they never suspect is the dangerous one. The general case for collecting these records is in the records to obtain before leaving a dental clinic abroad.

What you can reasonably control

You cannot control the prevalence of resistant organisms in a region you travel to, and you certainly cannot screen yourself at the airport. What you can control is the one variable that turns a silent importation into a manageable medical fact: visibility.

Tell every clinician who treats you afterward that you had a procedure abroad, where, when, what was done, whether you stayed in a facility, and whether you were given antibiotics. Carry your operative and discharge records home. Mention the history specifically if you are admitted to hospital, develop a wound that will not heal, or run a fever in the weeks after. None of this is about panic, and the great majority of travellers will never need any of it. It is about refusing to let the importation stay invisible. The same theme of unmonitored medical events after travel runs through a drug interaction voided by overseas antibiotics and through the warning on day-four swelling that is not normal, both of which depend on a home clinician knowing what happened abroad.

The bottom line

Carrying a resistant organism is not the same as being infected by one, and most people who travel for care come home with nothing of consequence. I will not inflate a documented but uneven risk into a universal fear. But the narrow claim stands on solid ground: medical tourism is a recognised route by which a person can acquire a multidrug-resistant organism abroad and carry it home, often silently, into a system that has no idea it has arrived.

The danger is not the organism. It is the invisibility. Colonisation is quiet, the importation crosses the border without a symptom to report, and the resistance literature documents the route while honestly refusing to hand me a clean percentage for it. The lever you actually control is whether your home clinicians know what happened. Tell them where you were treated and what was done, carry your records, and flag the history before any future hospital stay. A known importation is a manageable one. An unknown one is the version that does damage. The methodology and disclosures pages set out how this publication weighs evidence like this.